The temporary pause will allow the company to investigate four neurovascular events seen in an external evaluation study.

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & ...

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...